ABSTRACT
Selective estrogen receptor modulators (SERMs) are a new class of drugs that provide a new option for addressing the health challenges of postmenopausal women. This review discusses the proposed mechanism of action of SERMs and describes clinical findings on raloxifene, a SERM now available for treating and preventing osteoporosis.
Footnotes
↵* Disclosure: Dr. Licata has received grant support from Eli Lilly and Company, which manufactures raloxifene; Drs. Ciatcia, Wong, and Draper are employees of Eli Lilly and Company.
- Copyright © 2000 The Cleveland Clinic Foundation. All Rights Reserved.
Jump to section
Related Articles
Cited By...
- No citing articles found.